Can This Next-Gen Obesity Drug Save Novo Nordisk?

AI Briefing

• – Novo Nordisk's next-generation obesity drug has shown promising results in clinical trials.
• – The company is facing increased competition from rivals like Eli Lilly and Merck.
• – Novo Nordisk's stock price has plummeted in recent months despite the positive trial data.